Skip to main content
. 2020 Jun 30;13:80. doi: 10.3389/fnmol.2020.00080

TABLE 3.

Clinical data of PD patients and healthy controls included in the tandem mass tag-based proteomics analysis.

Variable (SEM/%) HC (27) PD (30) p-value Variable (SEM/%) HC (27) PD (30) p-value
Age (year) 66.59 ± 1.14 69.17 ± 1.50 0.184 HbA1c (%) 5.99 ± 0.18 6.17 ± 0.19 0.515
Gender, Male (%) 14 (51.9%) 19 (63.3%) 0.381 TC (mmol/L) 4.33 ± 0.17 4.32 ± 0.16 0.952
Smoking history (%) 9 (33.3%) 7 (23.3%) 0.402 TG (mmol/L) 1.49 ± 0.15 1.23 ± 0.14 0.206
Alcohol consumption (%) 3 (11.1%) 1 (3.3%) 0.53 HDL-C (mmol/L) 1.21 ± 0.08 1.24 ± 0.09 0.858
Hypertension (%) 15 (55.6%) 13 (43.3%) 0.357 LDL-C (mmol/L) 2.81 ± 0.15 2.73 ± 0.13 0.679
Diabetes mellitus (%) 2 (7.4%) 5 (16.7%) 0.51 Apo-A1 (g/L) 1.31 ± 0.05 1.30 ± 0.05 0.93
Hypercholesterolemia (%) 4 (14.8%) 6 (20.0%) 0.869 Apo-B (g/L) 0.89 ± 0.04 0.85 ± 0.04 0.403
BMI (kg/m2) 23.95 ± 0.69 22.79 ± 0.58 0.197 Lpa (mg/L) 201.19 ± 48.58 270.04 ± 66.49 0.407
UPDRS score / 38.49 ± 3.98 / Hoehn-Yahr score / 2.40 ± 0.16 /

PD, Parkinson’s disease; SEM, standard error of the mean; HC, healthy control; HbA1c, hemoglobin A1c; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; BMI, body mass index; Lpa, lipoprotein a; UPDRS, Unified Parkinson’s Disease Rating Scale.